Wuxi Biologics (cayman) Inc. · HKEX:2269
Wuxi Biologics (cayman) — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
37 slides from Wuxi Biologics (cayman)'s conference presentation, Jan 11, 2026
Slide 1: Inside Information: Presentation at 2026 Annual Healthcare Conference
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia
Slide 2: Announcement: business performance and outlook
As disclosed in the Presentation, the Group’s business and financial performance have remained strong with 209 newly added projects resulting in a total of 945 projects (including 74 phase III and 25 CMO (commercial manufacturing) projects) in 2025. In addition, the Group’s Research (R) platform sus
Slide 3: A Scaled CRDMO Platform Delivering Sustainable High Growth
A Scaled CRDMO Platform Delivering Sustainable High Growth Chris Chen, PhD 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 Stock Code: 2269.HK
Slide 4: Forward-Looking Statements; Use of Adjusted Financial Measures
Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe
Slide 5: Contents
CONTENTS A CRDMO Model for 01 Global Success 02 Business Update Strategic Footprint Expansion Technology Leadership 03 04 ESG as a Core Enabler of 05 Long-term Business Strategy 06 Summary & Outlook
Slide 6: A CRDMO Model for Global Success
A CRDMO Model for Global Success: 01 End-to-End Platform at Scale, Trusted by Global Clients
Slide 7: A Scaled, Integrated CRDMO+ Platform to Advance Biologics Globally
A Scaled, Integrated CRDMO+ Platform to Advance Biologics Globally Vision Every biologic can be made Accelerating the discovery, development, & Mission manufacturing of biologics for global partners & patients Follow + Win the Molecule CRDMO+ Pillars Client+ Global+ Innovation+ Agility+ Enable Scale
Slide 8: An End-to-End Biologics Platform Across the Full Lifecycle
An End-to-End Biologics Platform Across the Full Lifecycle We offer end-to-end CRDMO services, with flexible a la carte options C R Target Selection D M O Contract Cell Line Engineering DS GMP Manufacturing One partner Services Reagent Generation & Assay Development Assay Development DP
Slide 9: Driving Value for Our Clients
Winning the 2025 Global Customer Value Leadership Award Award-Recognized Execution with Proven Client Outcomes Filing Experience Supported 600+ IND submissions globally Driving value for our clients Commercial Strength Supported 25 commercial programs & 74 Phase III projects Reliability1 Over the pa
Slide 10: Business Updates
02 Business Updates
Slide 11: Research Services: Accelerating Deal Momentum & Platform Inflection
Research Services: Accelerating Deal Momentum & Platform Inflection Research Services sustained strong 2024 business momentum into 2025, with accelerating CD3 TCE deal activities signaling a platform inflection • Upfront payments & total payments for Research services reached another record year in
Slide 12: 50+ Active Research Services Partnerships with Global Innovators
50+ Active Research Services Partnerships with Global Innovators R Project Distribution by Phase CMO e.g. Gloria PD-1, CStone PD-L1; low-single digit royalty e.g. RCUS/GILD PD-1; royalty 7 - 10% of drug sales; Phase III 50%+ of programs are sponsored by Chia Tai Tianqing CD3 bispecific; low-single d
Slide 13: Record Project Wins & Funnel Progression through FY25
Record Project Wins & Funnel Progression through FY25 • Capitalizing on its leading technology, proven execution, and expanding global reach, the Company added 209 new WuXiBodyTM OMT Platform ADC Platform SDArBodYTM integrated projects in 2025, reinforcing its role as a partner of choice for biophar
Slide 14: Rich Pipeline across All Biologics Modalities
Rich Pipeline across All Biologics Modalities Total 945 • 369 First-in-class programs Integrated (1) 817 16% • 196 bi- & multi-specifics covering different formats. 341 Leveraging the Company’s deep expertise and end- mAb 4% 328 to-end capabilities, WuXi Biologics has captured expanding market oppor
Slide 15: Three High-Growth Modalities Powering Accelerated Growth
Three High-Growth Modalities Powering WuXi Biologics’ Accelerated Growth 3 Bi- & Multi-Specifics ADC mAb & Other Proteins • 196 in pipeline, fastest growing modality at WuXi • 252 ADCs in pipeline, high • 473 mAbs & other proteins Biologics. growth modality at WuXi in pipeline, with multiple o 3 cur
Slide 16: Bi- & Multi-Specifics as Most Exciting Growth Engine
Bi- & Multi-Specifics as WuXi Biologics’ Most Exciting Growth Engine Bi- & Multi-Specifics “R” Nearly 20 royalty-bearing • Close to 20 bi- & multi-specifics currently in Research Services ADC projects partnerships, eligible for potential milestones & royalties • Bi- & multi-specifics now match ADCs
Slide 17: A Proven Global Regulatory & Quality Track Record
A Proven Global Regulatory & Quality Track Record Regulatory Inspections and License Approvals 46 global regulatory inspections passed, including 22 EMA & FDA inspections 136 facility license approvals and a 100% success in GMP inspections 15 facilities certified for GMP manufacturing 1,800+ client
Slide 18: Scheduled PPQs Provide Strong Visibility into Future CMO Growth
Scheduled PPQs Provide Strong Visibility into Future CMO Growth # PPQs1 (by year) • 28 PPQs completed in 2025 and 34 PPQs are scheduled for 2026, indicating robust 34 28 momentum of 22 10 16 16 Manufacturing Services. 6 5 2019 2020 2021 2022 2023 2024 2025 2026E • 34 PPQs scheduled for 2026E based o
Slide 19: Expanding Phase III & CMO Pipeline Drives Future Manufacturing Growth
Expanding Phase III & CMO Pipeline Drives Future Manufacturing Growth CMO project # Phase III project # 99 87 75 54 74 66 41 51 30 37 32 28 24 21 (1) 25 17 2 9 2020 2021 2022 2023 2024 2025 • 74 late-stage & 25 CMO projects as of 2025, providing a solid foundation for manufacturing revenue. Contin
Slide 20: Strategic Footprint Expansion
Strategic Footprint Expansion: Scaling Integrated CRDMO Capabilities in the U.S. & Asia 03
Slide 21: Increasing Strategic Investments in the U.S.
Increasing Strategic Investments in the U.S. to Enable Integrated Biologics Services Drug Substance Seamless transfer of materials, 5-hour drive samples, & products across sites MFG11: Worcester, MA (2028) • Late-stage & commercial manufacturing • 6 x 6,000 L (36,000 L) capacity Process Development
Slide 22: Singapore: Scaling an End-to-End Biologics Hub
Singapore: Scaling an End-to-End Biologics Hub 15 months from pilling start to WuXi XDC Mechanical Completion Jan 2024 Mar 2024 + Construction for a new modular Drug Product (DP) facility has begun. Design work is underway for a planned drug substance (DS) modular facility. Nov 2024 Aug 2024 + Mecha
Slide 23: Expanding CRDMO Network into the Middle East Through Qatar Partnership
Expanding CRDMO Network into the Middle East Through Strategic Qatar Partnership On December 2, 2025, WuXi Biologics announced the signing of a MOU with the Qatar Free Zones Authority (QFZ). Why Qatar Strengthens global operating resilience through geographic diversification A strategic overseas
Slide 24: Technology Leadership
Technology Leadership： Driving Differentiated Growth & Economics 04
Slide 25: Differentiated TCE, Bi- & Multi-specific Ab Platforms
Differentiated TCE, bi- & multi-specific Ab Platforms Enabling Partner Pipelines CD3 TCEs Unique binding epitope Cynomolgus monkey cross-reactive Bispecific Technology Platform WuXiBodyTM Development Progress 40nM binding affinity (out-licensed, currently in collaboration) Fast-on & fast-off
Slide 26: Industry-leading Target Integration Cell Line Platform
Industry-leading Target Integration Cell Line Platform: 8g/L Titer with 50 Cells Screened & IND in 6 months WuXiaTM Random Integration Semi-Targeted Integration Targeted Integration Platform Technology 2010 2019 2025 Innovation 2.0 3.0 Clone Diversity Clone Stability Current Historical ~50 cells scr
Slide 27: Nearly a Decade of Proven Large-Scale Manufacturing Track Record
Nearly a Decade of Proven Large-Scale Manufacturing Track Record WuXi Biologics began large-scale manufacturing (≥6k L/batch) in 2017. To date, we have successfully delivered 352 batches of large-scale manufacturing Large-scale1 manufacturing capacity from Large-Scale Manufacturing Tailored Across 3
Slide 28: High Dose Delivery Technologies
High Dose Delivery Technologies Expanding Clinical & Commercial Options High Dose Delivery Three Core Technology Solutions High Concentration (up to 230 mg/mL) SC Large Volume & Self-administration SC Large Volume (2 mL→20 mL or larger) Hyaluronan Hyaluronidase Fragments 132 Viscosity (cP) 59
Slide 29: Comprehensive DP Development Across Modalities, Formulations & Delivery Formats
Comprehensive DP Development Across Modalities, Formulations & Delivery Formats mAbs, bi- & multi-specifics, fusion proteins, ADCs, enzymes, & more Vials, pre-filled syringes, and safety devices or autoinjectors Liquid, frozen, or lyophilized dosage forms High-throughput automation Liquid Vial Lyo V
Slide 30: Building the World's Leading Digital CRDMO
Building the World’s Leading Digital CRDMO 28
Slide 31: Digital Platforms Enhancing Speed, Quality & Operational Efficiency
Digital Platforms Enhancing Speed, Quality & Operational Efficiency Lab Core Operating Systems & Analytics Win & Serve Our Clients Manufacturing & Quality Control to Accelerate Discovery & Development DaVinci Client Portal BioFoundry EBR + Best-in-class digital client experience with + Digital twin
Slide 32: PatroLab: Bioprocess Digital Twin Platform
PatroLab™: A Platform Solution For Bioprocess Digital Twin Implementation at WuXi Biologics Raman Data Acquisition & Repository Process Knowledge Hub Process Orchestration Interface Raman Spectroscopy Multi-source data integration Model Visualization o In-line process data: OSI PI system o Off-line
Slide 33: ESG as a Core Enabler of Long-term Business Strategy
ESG as a Core Enabler of 05 Long-term Business Strategy
Slide 34: Trustworthy Partner with a Strong Sustainability Commitment
Trustworthy Partner with a Strong Sustainability Commitment Align with United Nations Sustainable Development Goals Join International Sustainable Development Initiatives Industry Leader with Outstanding ESG Performance Trusted Partner to Enable Global Clients DJSI World Indices MSCI ESG Ratings AAA
Slide 35: Summary & Outlook
Summary & Outlook 06
Slide 36: On Track to Deliver FY2025 with Sustained Growth Momentum into FY26
On Track to Deliver FY2025 with Sustained Growth Momentum into FY26 Summary Outlook • On track to deliver a strong FY2025 of top- & bottom-line growth • Bi- & multi-specifics as WuXi Biologics’ most exciting & fastest- • Business momentum continues growing modality, with strength across R, D, M Co
Slide 37: WuXi Biologics
WuXi Biologics Every Biologic Can Be Made | Premier | | | |
WuXi Biologics (Cayman) — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix